UMMY18067 / RPCI Lipe Lenalidomide IIT / Brea LipeResearch Question:
What is the safety of a peptide vaccine (called SVN53-67/M57-KLH) in treating patients
with newly diagnosed multiple myeloma (plasma cell leukemia) who are receiving chemotherapy?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase I trial studies the safety of SVN53-67/M57-KLH peptide vaccine in incomplete
Freund's adjuvant together with sargramostim in treating patients with newly diagnosed
multiple myeloma who are receiving lenalidomide maintenance therapy. Vaccines made
from survivin peptide may help the body build an effective immune response to kill
cancer cells that express survivin. Incomplete Freund's adjuvant may help stimulate
the body's immune response to a vaccine treatment. Colony-stimulating factors, such
as sargramostim, may increase the production of blood cells. Lenalidomide may stop
the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Giving SVN53-67/M57-KLH peptide vaccine in incomplete Freund's adjuvant and sargramostim
before or after the start of lenalidomide maintenance therapy may be a better treatment
for multiple myeloma.
Study Reference #: UMMY18067
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search